As a therapeutic strategy targeting the mTORC1 pathway, several studies have developed single or dual inhibitors targeting components of the PI3K-Akt-mTORC1 signaling cascade and have showed profound anti-leukemic effects on T-ALL cell lines or in vivo T-ALL models, suggesting the presence of a dominant oncogenic driver in this pathway [41, 42]. Here, AKT1 is linked to acute lymphoblastic leukemia.